Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aripiprazole for schizophrenia.

H G El-Sayeh1, C Morganti

  • 1Academic Unit of Psychiatry, University of Leeds, 15 Hyde Terrace, Leeds, West Yorkshire, UK, LS2 9LT.

The Cochrane Database of Systematic Reviews
|April 24, 2004
PubMed
Summary

Aripiprazole may effectively treat schizophrenia, reducing relapse and improving compliance compared to placebo. However, it shows similar efficacy and tolerability to other antipsychotics, with potential for insomnia but less risk of elevated prolactin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of dynamic three-dimensional culture on osteogenic potential of human periodontal ligament-derived mesenchymal stem cells entrapped in alginate microbeads.

Journal of periodontal research·2014
Same author

Substantivity of sunscreens: an appraisal of some quaternary ammonium sunscreens.

International journal of cosmetic science·2009
Same author

Aripiprazole for schizophrenia. Systematic review.

The British journal of psychiatry : the journal of mental science·2006
Same author

Aripiprazole for schizophrenia.

The Cochrane database of systematic reviews·2006
Same author

Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia.

The Cochrane database of systematic reviews·2006
Same author

Return to play after cervical spine injury.

Spine·2001

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Trials

Background:

  • Traditional antipsychotic drugs for schizophrenia often have limited efficacy and significant adverse effects.
  • Aripiprazole, an atypical antipsychotic, is proposed to offer improved efficacy with fewer side effects.

Purpose of the Study:

  • To systematically evaluate the clinical effectiveness of aripiprazole in treating schizophrenia and related psychoses.

Main Methods:

  • Conducted a comprehensive literature search of randomized controlled trials (RCTs) up to May 2003.
  • Included RCTs comparing aripiprazole against placebo, typical, or other atypical antipsychotics.
  • Employed intention-to-treat analysis, calculating relative risks (RR) and weighted mean differences (WMD) with confidence intervals (CI).

Main Results:

  • Aripiprazole significantly reduced relapse rates and improved study protocol compliance compared to placebo.
  • Compared to typical antipsychotics, aripiprazole showed no significant differences in global state, mental state, or quality of life, with similar adverse effect profiles.
  • Aripiprazole demonstrated fewer instances of elevated prolactin and QTc interval prolongation when compared to risperidone.

Conclusions:

  • Aripiprazole appears effective for schizophrenia but offers limited advantages over existing typical and atypical antipsychotics.
  • Potential side effects include insomnia (vs. perphenazine) but may involve less risk of hyperprolactinemia and QTc prolongation (vs. risperidone).
  • Further well-reported, pragmatic RCTs are needed to establish aripiprazole's definitive role in clinical practice.

Related Experiment Videos